01—Abstract
Summary
Summary of the 8-K filed February 2, 2026. Cited figures are marked; the original filing is the authoritative source.
CME Group Inc. (CME) has filed a Current Report on Form 8-K dated February 2, 2026, to disclose important pricing changes communicated to its clients through Special Executive Report 9676.
This announcement, made effective February 1, 2026, is being shared proactively with investors and the market, though specific details of the pricing adjustments are not included in this 8-K filing. Investors should note that this information is provided under Regulation FD Disclosure and is not deemed 'filed' for purposes of Section 18 of the Exchange Act, meaning it does not carry the same regulatory implications as a traditional filing.
02—Key points
Key Highlights
- CME Group Inc. announced pricing changes to clients via Special Executive Report 9676, effective February 1, 2026.
- The company has made the notice of these pricing changes available on its website.
- This filing is made under Item 7.01 (Regulation FD Disclosure).
- Information furnished under Item 7.01 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
- The filing does not incorporate the disclosed information by reference into other SEC filings unless expressly stated.
- No specific financial statements or new quantitative data are presented in this report, beyond the disclosure of pricing adjustments.
03—Questions
Frequently Asked Questions
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to publicly disclose that CME Group Inc. has communicated pricing changes to its clients. This is done to ensure fair and transparent dissemination of material information to all market participants.
What are the specific details of the pricing changes?
This 8-K filing does not provide the specific details of the pricing changes. It only states that a notice (Special Executive Report 9676) regarding these changes was communicated to clients and posted on the company's website.
How will this pricing change potentially affect CME Group's financial performance?
The impact of these pricing changes on CME Group's financial performance is not detailed in this filing. Investors would need to refer to future financial reports or the Special Executive Report 9676 (if accessible) for potential revenue or profitability implications.
Why is this disclosure made under Regulation FD?
Regulation FD (Fair Disclosure) requires that when a public company discloses material non-public information to certain persons (like clients), it must make that information available to the public simultaneously or promptly. This filing ensures that the market is aware of the pricing changes that were communicated to clients.
04—Continue